MedPath

Expanded Access to Ziftomenib

Conditions
Acute Lymphoblastic Leukemia, With Appropriate Mutations
Acute Myeloid Leukemia, With NPM1 Mutations
Registration Number
NCT05738538
Lead Sponsor
Kura Oncology, Inc.
Brief Summary

Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL) with KMT2A rearrangements, or Acute Myeloid Leukemia (AML), with NPM1 mutations or KMT2A rearrangements.

To request access, use Responsible Party contact information provided in this record.

Expanded access for ziftomenib is only available in the United States.

Detailed Description

• Subsection Condition:

* NPM1 mutation in AML patients

* KMT2A rearrangement in AML patients

* KMT2A rearrangement in ALL patients

Recruitment & Eligibility

Status
AVAILABLE
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria
  • Diagnosed with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL).
  • Adult, ages 18+.
  • Has exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition. For newly diagnosed AML patients with either NPM1-mutant, or KMT2A-rearranged AML, ziftomenib therapy will be considered for patients not eligible for ongoing clinical trials. In the case of patients with KMT2A-rearranged AML, Expanded Access to ziftomenib will only be provided for use in combination with FDA-approved therapies currently under clinical investigation at Kura Oncology (e.g., venetoclax + azacitidine, cytarabine + daunorubicin).
  • Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
  • Meets any other pertinent medical criteria for access to the investigational drug, as established by Kura Oncology.

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.